C-MER Medical Holdings (SEHK:3309) - Cotización, noticias y análisis

Resumen de acción 3309

C-MER Eye Care Holdings Limited, sociedad de cartera de inversiones, presta servicios oftalmológicos bajo la marca C-MER Dennis Lam en Hong Kong y China continental.

Acerca de la empresa

3309 análisis fundamental
Puntuación del copo de nieve
Valoración	2/6
Crecimiento futuro	0/6
Resultados anteriores	2/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Cotiza un 66.6% por debajo de nuestra estimación de su valor justo

Ha pasado a ser rentable este año

Análisis de riesgos

Los beneficios han disminuido un 23.6% al año en los últimos 5 años

Competidores de C-MER Medical Holdings Limited

China Resources Medical Holdings

SEHK:1515

HK$4.6b

Chaoju Eye Care Holdings

SEHK:2219

HK$2.0b

Rici Healthcare Holdings

SEHK:1526

HK$1.9b

Honliv Healthcare Management Group

SEHK:9906

HK$1.3b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de C-MER Medical Holdings
Precios históricos de las acciones
Precio actual de la acción	HK$2.78
Máximo en 52 semanas	HK$4.20
Mínimo de 52 semanas	HK$2.39
Beta	0.57
11 mes Cambio	-6.71%
Variación en 3 meses	-1.77%
Cambio de 1 año	-26.65%
3Variación en 3 años	-72.14%
Variación en 5 años	-53.28%
Variación desde la OPV	-45.60%

Noticias y actualizaciones recientes

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

Recent updates

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Jan 17

Rentabilidad de los accionistas

	3309	HK Healthcare	Mercado HK
7D	-4.1%	-0.6%	-1.4%
1Y	-26.6%	-22.6%	1.3%

Rentabilidad vs. Industria: Los resultados de 3309 fueron inferiores a los de la industria Hong Kong Healthcare, que obtuvo un rendimiento del -20.6% el año pasado.

Rentabilidad vs. Mercado: 3309 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.1% el año pasado.

Volatilidad de los precios

Is 3309's price volatile compared to industry and market?
3309 volatility
3309 Average Weekly Movement	4.1%
Healthcare Industry Average Movement	5.6%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	15.0%
10% least volatile stocks in HK Market	3.7%

Precio estable de las acciones: 3309 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 3309 (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2012	3,273	Dennis Lam	www.cmermedical.com

C-MER Eye Care Holdings Limited, sociedad de cartera de inversiones, presta servicios oftalmológicos bajo la marca C-MER Dennis Lam en Hong Kong y China continental. La empresa opera a través de cuatro segmentos: HK Medical Business, Ventas de consumibles médicos, Mainland China Ophthalmic Business y Mainland China Dental Business. Presta servicios dentales, oncológicos, de estética médica y de laboratorio; y se dedica a la venta de productos de ayuda a la visión, como gafas y lentillas, y consumibles médicos.

Resumen de fundamentos de C-MER Medical Holdings Limited

¿Cómo se comparan los beneficios e ingresos de C-MER Medical Holdings con su capitalización de mercado?
Estadísticas fundamentales de 3309
Capitalización bursátil	HK$3.48b
Beneficios(TTM)	HK$62.00m
Ingresos (TTM)	HK$1.92b

55.8x

Ratio precio-beneficio (PE)

1.8x

Ratio precio-ventas (PS)

¿Está 3309 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 3309
Ingresos	HK$1.92b
Coste de los ingresos	HK$1.31b
Beneficio bruto	HK$618.96m
Otros gastos	HK$556.96m
Beneficios	HK$62.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.05
Margen bruto	32.17%
Margen de beneficio neto	3.22%
Ratio deuda/patrimonio	1.2%

¿Cómo se ha desempeñado 3309 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 3309

Recompensas

Análisis de riesgos

Competidores de C-MER Medical Holdings Limited

SEHK:1515

HK$4.6b

SEHK:2219

HK$2.0b

SEHK:1526

HK$1.9b

SEHK:9906

HK$1.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Recent updates

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 12% to HK$4.50

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

A Look At The Intrinsic Value Of C-MER Eye Care Holdings Limited (HKG:3309)

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Capital Allocation Trends At C-MER Eye Care Holdings (HKG:3309) Aren't Ideal

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

Is C-MER Eye Care Holdings (HKG:3309) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

Executive Director exercised options to buy HK$1.7m worth of stock.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Update: C-MER Eye Care Holdings (HKG:3309) Stock Gained 25% In The Last Year

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de C-MER Medical Holdings Limited